Control of viral rebound through therapeutic immunization with DermaVir.
To reconstitute immune responses capable of eliminating infected cells and suppressing viral load during chronic retroviral infection. : A topical, DNA-based therapeutic immunization (DermaVir) was designed to express most of the regulatory and structural viral genes in dendritic cells. DermaVir alone and in combination with antiretroviral drugs was tested in chronically SIV-infected macaques. DermaVir provided virological, immunological and clinical benefit for SIV-infected macaques during chronic infection and AIDS. In combination with antiretroviral drugs, DermaVir augmented SIV-specific T-cell responses and enhanced control of viral load rebound during treatment interruptions. The results indicate the feasibility of therapeutic immunization even in immune compromised hosts, and suggest that DermaVir can complement antiretroviral drugs to sustain suppression of HIV-1 replication.